MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
7.8M
Short interest
settlement 2026-10-15
4.1
Days to cover
-0.2 days vs prior
52.1%
Short share of volume
2026-11-02
292
Fails to deliver
settlement 2026-10-01
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in MLTX is 7,833,997 shares, down 1,113,909 shares over the last month. Over the last 48 readings it ranged from 3,856,500 shares (14 November 2025) to 8,947,906 shares (15 September 2026). At the reported average volume of 1.9M shares a day that is 4.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/mltx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 7,833,997 | -2.7% | 1,920,537 | 4.08 |
| 2026-09-30 | 8,048,665 | -10.1% | 1,901,006 | 4.23 |
| 2026-09-15 | 8,947,906 | +25.2% | 1,473,823 | 6.07 |
| 2026-08-31 | 7,144,513 | +4.8% | 1,070,171 | 6.68 |
| 2026-08-14 | 6,819,147 | +19.2% | 1,615,874 | 4.22 |
| 2026-07-31 | 5,721,976 | -9.7% | 864,693 | 6.62 |
| 2026-07-15 | 6,334,566 | -3.4% | 1,268,600 | 4.99 |
| 2026-06-30 | 6,557,634 | +23.3% | 1,856,799 | 3.53 |
| 2026-06-15 | 5,319,238 | -4.5% | 736,814 | 7.22 |
| 2026-05-29 | 5,568,411 | +1.8% | 803,977 | 6.93 |
| 2026-05-15 | 5,467,746 | -13.5% | 1,095,540 | 4.99 |
| 2026-04-30 | 6,320,177 | -5.0% | 683,059 | 9.25 |
| 2026-04-15 | 6,654,522 | -14.2% | 1,569,884 | 4.24 |
| 2026-03-31 | 7,757,169 | +6.1% | 997,078 | 7.78 |
| 2026-03-13 | 7,313,594 | +3.9% | 799,861 | 9.14 |
| 2026-02-27 | 7,036,421 | -3.2% | 1,607,440 | 4.38 |
| 2026-02-13 | 7,271,326 | +3.6% | 1,052,124 | 6.91 |
| 2026-01-30 | 7,017,037 | -2.3% | 1,415,292 | 4.96 |
| 2026-01-15 | 7,182,036 | +24.3% | 5,630,446 | 1.28 |
| 2025-12-31 | 5,776,842 | +18.0% | 1,169,409 | 4.94 |
| 2025-12-15 | 4,894,840 | +14.6% | 1,994,310 | 2.45 |
| 2025-11-28 | 4,270,493 | +10.7% | 1,974,838 | 2.16 |
| 2025-11-14 | 3,856,500 | -21.4% | 2,341,428 | 1.65 |
| 2025-10-31 | 4,907,886 | +0.3% | 2,774,119 | 1.77 |
| 2025-10-15 | 4,890,713 | -15.3% | 9,798,167 | 1.00 |
| 2025-09-30 | 5,771,368 | +16.6% | 11,199,322 | 1.00 |
| 2025-09-15 | 4,948,787 | -4.4% | 829,243 | 5.97 |
| 2025-08-29 | 5,176,424 | -3.5% | 431,521 | 12.00 |
| 2025-08-15 | 5,366,017 | -12.5% | 409,742 | 13.10 |
| 2025-07-31 | 6,132,791 | -3.3% | 527,177 | 11.63 |
| 2025-07-15 | 6,344,466 | +4.5% | 471,251 | 13.46 |
| 2025-06-30 | 6,071,916 | -0.8% | 403,627 | 15.04 |
| 2025-06-13 | 6,118,052 | -3.1% | 1,102,904 | 5.55 |
| 2025-05-30 | 6,312,098 | +4.5% | 217,604 | 29.01 |
| 2025-05-15 | 6,040,928 | -0.9% | 374,868 | 16.11 |
| 2025-04-30 | 6,096,506 | -8.1% | 474,856 | 12.84 |
| 2025-04-15 | 6,631,703 | +4.5% | 485,394 | 13.66 |
| 2025-03-31 | 6,346,643 | -12.3% | 544,441 | 11.66 |
| 2025-03-14 | 7,239,529 | -2.6% | 309,728 | 23.37 |
| 2025-02-28 | 7,435,921 | -7.6% | 367,869 | 20.21 |
| 2025-02-14 | 8,045,590 | +4.7% | 286,601 | 28.07 |
| 2025-01-31 | 7,681,803 | -1.6% | 575,246 | 13.35 |
| 2025-01-15 | 7,802,648 | -3.4% | 488,671 | 15.97 |
| 2024-12-31 | 8,079,939 | +0.5% | 221,477 | 36.48 |
| 2024-12-13 | 8,038,437 | +0.5% | 159,851 | 50.29 |
| 2024-11-29 | 7,997,729 | -0.0% | 175,252 | 45.64 |
| 2024-11-15 | 8,000,568 | -0.8% | 251,583 | 31.80 |
| 2024-10-31 | 8,064,559 | -1.0% | 194,111 | 41.55 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of MLTX volume is 52.1%, up 2.4 points over the last five sessions. Over the last 30 readings it ranged from 16.0% (22 September 2026) to 59.6% (9 October 2026). The latest reading is 9.8 points above the 30-session average of 42.3%, on 356K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 185K | 356K | 52.1% | 0 |
| 2026-10-30 | 151K | 394K | 38.4% | 0 |
| 2026-10-29 | 727K | 1.6M | 46.0% | 18,524 |
| 2026-10-28 | 185K | 432K | 42.8% | 0 |
| 2026-10-27 | 137K | 358K | 38.3% | 0 |
| 2026-10-26 | 299K | 602K | 49.7% | 0 |
| 2026-10-23 | 348K | 771K | 45.1% | 0 |
| 2026-10-22 | 1.0M | 2.3M | 43.2% | 0 |
| 2026-10-21 | 177K | 350K | 50.6% | 0 |
| 2026-10-20 | 161K | 372K | 43.1% | 1,099 |
| 2026-10-19 | 157K | 290K | 54.2% | 0 |
| 2026-10-16 | 181K | 341K | 53.2% | 665 |
| 2026-10-15 | 86K | 320K | 27.0% | 0 |
| 2026-10-14 | 321K | 698K | 46.0% | 126 |
| 2026-10-13 | 391K | 814K | 48.1% | 0 |
| 2026-10-12 | 119K | 381K | 31.2% | 0 |
| 2026-10-09 | 566K | 950K | 59.6% | 0 |
| 2026-10-08 | 1.1M | 1.9M | 58.4% | 315 |
| 2026-10-07 | 214K | 474K | 45.1% | 0 |
| 2026-10-06 | 301K | 1.6M | 18.7% | 1,312 |
| 2026-10-05 | 270K | 957K | 28.2% | 0 |
| 2026-10-02 | 212K | 759K | 27.9% | 30,511 |
| 2026-10-01 | 255K | 493K | 51.7% | 0 |
| 2026-09-30 | 293K | 623K | 47.1% | 0 |
| 2026-09-29 | 270K | 640K | 42.1% | 71 |
| 2026-09-28 | 194K | 599K | 32.4% | 4 |
| 2026-09-25 | 431K | 928K | 46.4% | 0 |
| 2026-09-24 | 386K | 920K | 42.0% | 261 |
| 2026-09-23 | 471K | 1.1M | 44.5% | 321 |
| 2026-09-22 | 161K | 1.0M | 16.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 1 October 2026, the fails-to-deliver balance in MLTX is 292 shares, down 1,833 shares over the last settlement date. Over the last 30 readings it ranged from 8 shares (29 June 2026) to 427,783 shares (13 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-01 | 292 | $11.70 | $3K |
| 2026-09-02 | 2,125 | $15.13 | $32K |
| 2026-08-31 | 444 | $14.99 | $7K |
| 2026-08-27 | 1,071 | $15.62 | $17K |
| 2026-08-24 | 500 | $15.76 | $8K |
| 2026-08-21 | 3,880 | $15.87 | $62K |
| 2026-08-19 | 65 | $16.34 | $1K |
| 2026-08-14 | 2,529 | $16.50 | $42K |
| 2026-08-11 | 12,121 | $17.33 | $210K |
| 2026-08-05 | 52 | $17.93 | $932 |
| 2026-08-03 | 80 | $18.44 | $1K |
| 2026-07-20 | 500 | $19.68 | $10K |
| 2026-07-17 | 53 | $19.01 | $1K |
| 2026-07-16 | 13,154 | $19.96 | $263K |
| 2026-07-13 | 427,783 | $20.36 | $8.7M |
| 2026-07-10 | 318,500 | $19.93 | $6.3M |
| 2026-07-09 | 89,052 | $19.07 | $1.7M |
| 2026-07-08 | 110,872 | $19.15 | $2.1M |
| 2026-06-30 | 53,383 | $19.91 | $1.1M |
| 2026-06-29 | 8 | $19.90 | $159 |
| 2026-06-26 | 9,796 | $19.99 | $196K |
| 2026-06-11 | 1,504 | $17.49 | $26K |
| 2026-06-04 | 16 | $18.27 | $292 |
| 2026-05-29 | 16 | $18.68 | $299 |
| 2026-05-28 | 3,751 | $18.41 | $69K |
| 2026-05-19 | 1,000 | $16.44 | $16K |
| 2026-05-18 | 2,000 | $17.55 | $35K |
| 2026-05-14 | 902 | $18.41 | $17K |
| 2026-04-20 | 10,534 | $18.34 | $193K |
| 2026-03-04 | 20,600 | $17.69 | $364K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for MLTX in the last 90 days. The most recent filings are listed below. Latest filing: Reich Kristian (Chief Scientific Officer) on 2026-07-27.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-27 | Reich Kristian | Chief Scientific Officer | Sell | 1K | $20.00 | $22K | 2.7M |
| 2026-07-22 | Reich Kristian | Chief Scientific Officer | Sell | 2K | $20.00 | $49K | 2.7M |
| 2026-07-21 | Reich Kristian | Chief Scientific Officer | Sell | 50K | $20.02 | $1.0M | 2.7M |
| 2026-07-20 | Reich Kristian | Chief Scientific Officer | Sell | 44K | $20.09 | $878K | 2.8M |
| 2026-07-15 | Reich Kristian | Chief Scientific Officer | Sell | 16K | $20.01 | $322K | 2.8M |
| 2026-07-10 | Santos da Silva Jorge | Chief Executive Officer | Sell | 68K | $20.02 | $1.4M | 2.8M |
| 2026-07-09 | Santos da Silva Jorge | Chief Executive Officer | Sell | 34K | $20.01 | $679K | 2.8M |
| 2026-07-01 | Santos da Silva Jorge | Chief Executive Officer | Sell | 48K | $20.03 | $957K | 2.9M |
| 2026-06-22 | Bodenstedt Matthias | Chief Financial Officer | Sell | 39K | $22.04 | $862K | 1.1M |
| 2026-06-18 | Bodenstedt Matthias | Chief Financial Officer | Sell | 3K | $19.60 | $55K | 1.2M |
| 2026-06-17 | Reich Kristian | Chief Scientific Officer | Sell | 50K | $19.43 | $972K | 2.8M |
| 2026-06-17 | Bodenstedt Matthias | Chief Financial Officer | Sell | 15K | $19.68 | $297K | 1.2M |
| 2026-06-16 | Reich Kristian | Chief Scientific Officer | Sell | 50K | $18.70 | $935K | 2.9M |
| 2026-06-15 | Reich Kristian | Chief Scientific Officer | Sell | 50K | $18.89 | $945K | 2.9M |
| 2026-05-11 | Bodenstedt Matthias | Chief Financial Officer | Sell | 14K | $20.02 | $273K | 1.2M |
| 2026-04-14 | Bodenstedt Matthias | Chief Financial Officer | Sell | 2K | $19.56 | $47K | 1.2M |
| 2026-04-13 | Santos da Silva Jorge | Chief Executive Officer | Sell | 52K | $18.23 | $946K | 2.9M |
| 2026-04-10 | Bodenstedt Matthias | Chief Financial Officer | Sell | 2K | $19.51 | $38K | 1.2M |
| 2026-04-10 | Santos da Silva Jorge | Chief Executive Officer | Sell | 98K | $18.41 | $1.8M | 3.0M |
| 2026-04-09 | Bodenstedt Matthias | Chief Financial Officer | Sell | 86K | $18.94 | $1.6M | 1.2M |
| 2026-03-31 | LAMPERT MARK N | Director,TenPercentOwner | Sell | 249K | $16.79 | $4.2M | 1.0M |
| 2026-03-31 | LAMPERT MARK N | Director,TenPercentOwner | Sell | 1.6M | $16.79 | $26.3M | 6.6M |
| 2026-03-31 | LAMPERT MARK N | Director,TenPercentOwner | Sell | 1.9M | $16.79 | $32.4M | 8.3M |
| 2026-03-31 | BVF PARTNERS L P/IL | Director, 10% owner | Sell | 249K | $16.79 | $4.2M | 1.0M |
| 2026-03-31 | BVF PARTNERS L P/IL | Director, 10% owner | Sell | 1.6M | $16.79 | $26.3M | 6.6M |
| 2026-03-31 | BVF PARTNERS L P/IL | Director, 10% owner | Sell | 1.9M | $16.79 | $32.4M | 8.3M |
| 2026-01-07 | Bodenstedt Matthias | Chief Financial Officer | Grant | 354K | $0.00 | $0 | 1.3M |
| 2025-12-19 | Santos da Silva Jorge | Chief Executive Officer | Conversion | 196K | price not stated in the filing | not stated | 3.1M |
| 2025-12-19 | Santos da Silva Jorge | Chief Executive Officer | Returned to company | 196K | price not stated in the filing | not stated | 0 |
| 2025-12-19 | Reich Kristian | Chief Scientific Officer | Conversion | 35K | price not stated in the filing | not stated | 35K |
| 2025-12-19 | Reich Kristian | Chief Scientific Officer | Returned to company | 35K | price not stated in the filing | not stated | 0 |
| 2025-12-19 | Bodenstedt Matthias | Chief Financial Officer | Returned to company | 294K | price not stated in the filing | not stated | 0 |
| 2025-12-19 | Bodenstedt Matthias | Chief Financial Officer | Conversion | 294K | price not stated in the filing | not stated | 922K |
| 2025-12-09 | Santos da Silva Jorge | Chief Executive Officer | Sell | 70K | $14.49 | $1.0M | 2.9M |
| 2025-12-09 | Reich Kristian | Chief Scientific Officer | Sell | 73K | $14.43 | $1.1M | 0 |
| 2025-12-08 | Santos da Silva Jorge | Chief Executive Officer | Sell | 130K | $15.08 | $2.0M | 2.9M |
| 2025-12-08 | Reich Kristian | Chief Scientific Officer | Sell | 130K | $15.08 | $2.0M | 73K |
| 2025-10-08 | Bodenstedt Matthias | Chief Financial Officer | Buy | 11K | $9.09 | $99K | 628K |
| 2025-09-30 | Cormorant Global Healthcare Master Fund, LP | Other | Sell | 6K | $6.96 | $41K | 2.0M |
| 2025-09-30 | Chen Bihua | Former 10% Owner | Sell | 6K | $6.96 | $41K | 2.0M |
| 2025-09-29 | Cormorant Global Healthcare Master Fund, LP | Other | Sell | 2.8M | $6.61 | $18.5M | 2.0M |
| 2025-09-29 | Cormorant Global Healthcare Master Fund, LP | Other | Sell | 3.4M | $7.58 | $25.7M | 4.8M |
| 2025-09-29 | Cormorant Global Healthcare Master Fund, LP | Other | Sell | 71K | $9.38 | $664K | 8.4M |
| 2025-09-29 | Cormorant Global Healthcare Master Fund, LP | Other | Sell | 232K | $8.40 | $2.0M | 8.2M |
| 2025-09-29 | Chen Bihua | Former 10% Owner | Sell | 2.8M | $6.61 | $18.5M | 2.0M |
| 2025-09-29 | Chen Bihua | Former 10% Owner | Sell | 3.4M | $7.58 | $25.7M | 4.8M |
| 2025-09-29 | Chen Bihua | Former 10% Owner | Sell | 232K | $8.40 | $2.0M | 8.2M |
| 2025-09-29 | Chen Bihua | Former 10% Owner | Sell | 71K | $9.38 | $664K | 8.4M |
| 2025-09-02 | Reich Kristian | Chief Scientific Officer | Conversion | 49K | price not stated in the filing | not stated | 203K |
| 2025-09-02 | Reich Kristian | Chief Scientific Officer | Returned to company | 49K | price not stated in the filing | not stated | 35K |
| 2025-07-03 | Moukheibir Catherine | Director | Sell | 24K | $48.79 | $1.1M | 0 |
| 2025-07-03 | Moukheibir Catherine | Director | Exercise or conversion | 24K | $0.00 | $0 | 24K |
| 2025-02-27 | Bodenstedt Matthias | Chief Financial Officer | Grant | 96K | $0.00 | $0 | 617K |
| 2025-02-27 | Santos da Silva Jorge | Chief Executive Officer | Grant | 96K | $0.00 | $0 | 3.1M |
| 2025-01-20 | Reich Kristian | Chief Scientific Officer | Conversion | 112K | price not stated in the filing | not stated | 154K |
| 2025-01-20 | Reich Kristian | Chief Scientific Officer | Returned to company | 112K | price not stated in the filing | not stated | 84K |
| 2024-10-04 | Sturge Simon | Director | Sell | 171K | $53.72 | $9.2M | 172K |
| 2024-10-04 | BVF I GP LLC | Director,TenPercentOwner | Sell | 1.0M | $50.00 | $51.5M | 10.2M |
| 2024-10-04 | BVF I GP LLC | Director,TenPercentOwner | Sell | 133K | $50.00 | $6.6M | 1.3M |
| 2024-10-04 | BVF I GP LLC | Director,TenPercentOwner | Sell | 837K | $50.00 | $41.8M | 8.2M |
| 2024-02-29 | Santos da Silva Jorge | Chief Executive Officer | Sell | 5K | $55.89 | $265K | 3.0M |
| 2024-02-28 | Reich Kristian | Chief Scientific Officer | Sell | 32K | $55.00 | $1.8M | 2.9M |
| 2024-02-28 | Reich Kristian | Chief Scientific Officer | Sell | 28K | $55.00 | $1.5M | 42K |
| 2024-02-28 | Santos da Silva Jorge | Chief Executive Officer | Sell | 56K | $55.00 | $3.1M | 3.0M |
| 2024-02-27 | Reich Kristian | Chief Scientific Officer | Sell | 29K | $55.00 | $1.6M | 70K |
| 2024-02-27 | Reich Kristian | Chief Scientific Officer | Sell | 29K | $55.00 | $1.6M | 3.0M |
| 2024-02-27 | Santos da Silva Jorge | Chief Executive Officer | Sell | 63K | $55.00 | $3.5M | 3.0M |
| 2024-02-21 | Reich Kristian | Chief Scientific Officer | Sell | 569 | $55.30 | $31K | 100K |
| 2024-02-21 | Reich Kristian | Chief Scientific Officer | Sell | 509 | $55.31 | $28K | 3.0M |
| 2024-02-21 | Santos da Silva Jorge | Chief Executive Officer | Sell | 1K | $55.27 | $62K | 3.1M |
| 2024-02-20 | Reich Kristian | Chief Scientific Officer | Sell | 10K | $57.43 | $574K | 100K |
| 2024-02-20 | Santos da Silva Jorge | Chief Executive Officer | Sell | 20K | $57.44 | $1.1M | 3.1M |
| 2024-02-20 | Reich Kristian | Chief Scientific Officer | Sell | 10K | $57.45 | $575K | 3.0M |
| 2024-02-16 | Reich Kristian | Chief Scientific Officer | Sell | 10K | $60.15 | $602K | 110K |
| 2024-02-16 | Reich Kristian | Chief Scientific Officer | Sell | 10K | $60.15 | $602K | 3.0M |
| 2024-02-16 | Santos da Silva Jorge | Chief Executive Officer | Sell | 20K | $60.15 | $1.2M | 3.1M |
| 2024-02-15 | Reich Kristian | Chief Scientific Officer | Sell | 10K | $60.16 | $602K | 120K |
| 2024-02-15 | Reich Kristian | Chief Scientific Officer | Sell | 10K | $60.17 | $602K | 3.0M |
| 2024-02-15 | Santos da Silva Jorge | Chief Executive Officer | Sell | 20K | $60.18 | $1.2M | 3.1M |
| 2024-02-14 | Reich Kristian | Chief Scientific Officer | Sell | 10K | $62.42 | $624K | 3.0M |
| 2024-02-14 | Reich Kristian | Chief Scientific Officer | Sell | 10K | $62.43 | $624K | 130K |
| 2023-12-20 | Bodenstedt Matthias | Chief Financial Officer | Sell | 5K | $58.34 | $307K | 521K |
| 2023-12-19 | Bodenstedt Matthias | Chief Financial Officer | Sell | 95K | $59.22 | $5.6M | 526K |
| 2023-10-05 | Cormorant Private Healthcare Fund II, LP | TenPercentOwner | Buy | 59K | $59.90 | $3.5M | 8.5M |
| 2023-10-04 | Cormorant Private Healthcare Fund IV LP | TenPercentOwner | Buy | 68K | $57.32 | $3.9M | 8.4M |
| 2023-10-03 | Cormorant Private Healthcare Fund IV LP | TenPercentOwner | Buy | 150K | $57.25 | $8.6M | 8.4M |
| 2023-10-02 | Cormorant Private Healthcare Fund IV LP | TenPercentOwner | Buy | 75K | $57.37 | $4.3M | 8.2M |
| 2023-10-01 | Reich Kristian | Chief Scientific Officer | Conversion | 2.5M | price not stated in the filing | not stated | 3.0M |
| 2023-10-01 | Reich Kristian | Chief Scientific Officer | Conversion | 42K | price not stated in the filing | not stated | 140K |
| 2023-10-01 | Reich Kristian | Chief Scientific Officer | Returned to company | 42K | price not stated in the filing | not stated | 196K |
| 2023-10-01 | Reich Kristian | Chief Scientific Officer | Returned to company | 2.5M | price not stated in the filing | not stated | 0 |
| 2023-10-01 | Santos da Silva Jorge | Chief Executive Officer | Returned to company | 140K | price not stated in the filing | not stated | 217K |
| 2023-10-01 | Santos da Silva Jorge | Chief Executive Officer | Conversion | 3.0M | price not stated in the filing | not stated | 3.0M |
| 2023-10-01 | Santos da Silva Jorge | Chief Executive Officer | Returned to company | 3.0M | price not stated in the filing | not stated | 0 |
| 2023-10-01 | Santos da Silva Jorge | Chief Executive Officer | Conversion | 140K | price not stated in the filing | not stated | 3.2M |
| 2023-10-01 | Bodenstedt Matthias | Chief Financial Officer | Conversion | 63K | price not stated in the filing | not stated | 621K |
| 2023-10-01 | Bodenstedt Matthias | Chief Financial Officer | Returned to company | 63K | price not stated in the filing | not stated | 294K |
| 2023-10-01 | Sturge Simon | Director | Conversion | 343K | price not stated in the filing | not stated | 343K |
| 2023-10-01 | Sturge Simon | Director | Returned to company | 343K | price not stated in the filing | not stated | 0 |
| 2023-06-30 | Chen Bihua | TenPercentOwner | Buy | 800K | $50.00 | $40.0M | 4.9M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON8 Form 144 notices on file for MLTX worth $84.0M at the prices reported; 0 in the last 90 days worth $0. Latest: Reich Kristian filed on 2026-07-15 to sell 150,000 shares ($2.9M) from 2026-07-15.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-15 | Reich KristianOfficer | 150K | $2.9M | 0.204% | 2026-07-15 | UBS Financial Services, Inc. |
| 2026-06-30 | Santos da Silva JorgeOfficer, CEO | 150K | $3.0M | 0.204% | 2026-06-30 | UBS Financial Services, Inc. |
| 2026-06-15 | Reich KristianOfficer | 150K | $2.9M | 0.204% | 2026-06-15 | UBS Financial Services, Inc. |
| 2026-04-10 | Jorge Pedro Santos Radeck D SilvaCEO | 150K | $2.8M | 0.209% | 2026-04-10 | UBS Financial Services Inc |
| 2026-04-09 | Bodenstedt MatthiasOfficer, CFO | 161K | $3.0M | 0.224% | 2026-04-09 | UBS Financial Services, Inc. |
| 2026-03-31 | BVF PARTNERS L P/IL10% Stockholder, Affiliate of Director | 3.8M | $63.5M | 5.228% | 2026-03-31 | Goldman Sachs & Co. LLC |
| 2025-12-08 | Jorge Pedro Santos Radeck Da SilvaOfficer, Director, CEO | 200K | $3.0M | 0.314% | 2025-12-08 | UBS Financial Services Inc |
| 2025-12-08 | Kristian Dieter Johannes ReichOfficer, Director, Chief Scientific Officer | 203K | $3.0M | 0.319% | 2025-12-08 | UBS Financial Services Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON12 holders report 5% or more of MLTX in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is BVF PARTNERS L P/IL at 19.7% of the class (16,001,284 shares), filed 2026-06-29 for an event on 2026-06-25.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G | T. Rowe Price Investment Management, Inc.investment adviser | 4.3M | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Cormorant Asset Management, LPinvestment adviser, partnership | 3.2M | 4.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Bihua Chenparent holding company, individual | 3.2M | 4.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 8.0M | 9.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 8.0M | 9.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | David Kroinparent holding company, individual | 8.0M | 9.7% | 2026-06-30 |
| 2026-06-29 | 13D/Ano. 6 | BVF PARTNERS L P/ILinvestment adviser, partnership | 16.0M | 19.7% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | LAMPERT MARK Nindividual | 16.0M | 19.7% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | BVF INC/ILcorporation | 16.0M | 19.7% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | BVF GP HOLDINGS LLCother entity | 14.9M | 18.4% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 8.3M | 10.2% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | BVF I GP LLCother entity | 8.3M | 10.2% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 6.6M | 8.1% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | BVF II GP LLCother entity | 6.6M | 8.1% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | Biotechnology Value Trading Fund OS LPpartnership | 1.0M | 1.3% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | BVF Partners OS Ltd.corporation | 1.0M | 1.3% | 2026-06-25 |
| 2026-06-29 | 13D/Ano. 6 | Loy Spikeindividual | 26K | 0.0% | 2026-06-25 |
| 2025-11-14 | 13G/Ano. 1 | Behzad Aghazadehparent holding company, individual | 2.0M | 3.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Avoro Capital Advisors LLCinvestment adviser, other entity | 2.0M | 3.1% | 2025-09-30 |
| 2025-11-05 | 13G/Ano. 4 | FMR LLCparent holding company | 727K | 1.1% | 2025-09-30 |
| 2025-11-05 | 13G/Ano. 4 | Abigail P. Johnsonindividual | 727K | 1.1% | 2025-09-30 |
| 2025-10-01 | 13G/Ano. 2 | Chen Bihuaindividual, parent holding company | 2.0M | 3.1% | 2025-09-30 |
13F holders
Tracked managers holding MLTX at their latest 13F. JSON7 of the 30 tracked managers held MLTX at their latest 13F, $191.8M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $65.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 3.4M | $65.5M | 0.03% | +975K |
| Citadel Advisors | 2026-06-30 | 2.0M | $38.4M | 0.00% | +649K |
| Two Sigma Investments | 2026-06-30 | 1.7M | $33.4M | 0.02% | +593K |
| Point72 Asset Management | 2026-06-30 | 1.2M | $22.6M | 0.02% | -210K |
| Renaissance Technologies | 2026-06-30 | 643K | $12.5M | 0.02% | +366K |
| Millennium Management | 2026-06-30 | 636K | $12.4M | 0.00% | +60K |
| AQR Capital Management | 2026-06-30 | 359K | $7.0M | 0.00% | +313K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$196.0M of operating cash flow. As of 2026-06-30, cash was $477.9M against $99.5M of debt.
- Cash
- $477.9M
- Debt
- $99.5M
- Equity
- $428.2M
- Total assets
- $573.9M
- Shares outstanding
- 85,106,685
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$61.8M | n/a | -0.84 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$69.7M | n/a | -0.98 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$62.4M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$69.7M | n/a | -1.10 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$55.2M | n/a | -0.87 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$39.9M | n/a | -0.63 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$45.6M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$35.4M | n/a | -0.56 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$227.3M | -$196.0M | $35K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$118.9M | -$116.6M | $520K | $50 | n/a |
| FY 2023 | 2023-12-31 | n/a | -$36.0M | -$42.8M | $284K | $0 | n/a |
| FY 2022 | 2022-12-31 | n/a | -$50.0M | -$55.9M | $16K | $0 | n/a |
| FY 2021 | 2021-12-31 | n/a | -$4.5M | -$611K | n/a | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-01 from the cover page.
What this page is
MoonLake Immunotherapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows MoonLake Immunotherapeutics (MLTX), SEC CIK 1821586, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-01.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-15.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-10.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-27.JSON and CSV
- Company record
- EDGAR filing index for CIK 1821586Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of MLTX is sold short?
7,833,997 shares were held short at the 2026-10-15 settlement, 4.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is MLTX's daily short volume?
On 2026-11-02, 185,497 of the 355,692 MLTX shares reported to FINRA were sold short, 52.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does MLTX have fails to deliver?
The SEC's latest file shows 292 MLTX shares failed to deliver at settlement 2026-10-01. Fails are reported per settlement date and published twice a month with a lag.
Are MLTX insiders buying or selling?
No open-market insider trades were reported for MLTX in the last 90 days. The most recent filings are listed below. Latest filing: Reich Kristian (Chief Scientific Officer) on 2026-07-27.
Have MLTX insiders filed to sell?
8 Form 144 notices on file for MLTX worth $84.0M at the prices reported; 0 in the last 90 days worth $0. Latest: Reich Kristian filed on 2026-07-15 to sell 150,000 shares ($2.9M) from 2026-07-15.
Who owns 5% or more of MLTX?
12 holders report 5% or more of MLTX in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is BVF PARTNERS L P/IL at 19.7% of the class (16,001,284 shares), filed 2026-06-29 for an event on 2026-06-25.
What did MLTX report last quarter?
In FY 2025 it generated -$196.0M of operating cash flow. As of 2026-06-30, cash was $477.9M against $99.5M of debt.
Which tracked 13F managers own MLTX?
7 of the 30 tracked 13F managers held MLTX shares at their latest filing, $191.8M in all. The largest: D. E. Shaw & Co. (3.4M shares, $65.5M), Ken Griffin's Citadel Advisors (2.0M shares, $38.4M), Two Sigma Investments (1.7M shares, $33.4M), Steve Cohen's Point72 Asset Management (1.2M shares, $22.6M), Renaissance Technologies (643K shares, $12.5M), Izzy Englander's Millennium Management (636K shares, $12.4M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.